Clinical Trial Update: Optimal PeriproCeduraL AnticOagulation in Structural Transseptal Interventions [Phase 4]

View source ↗

Summary

A Phase 4 trial sponsored by the National Institute of Cardiology in Warsaw is evaluating optimal periprocedural anticoagulation during structural transseptal i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation
• Mitral Regurgitation

Snippet

Sponsor: National Institute of Cardiology, Warsaw, Poland | Conditions: Mitral Regurgitation, Atrial Fibrillation | Phase 4 | Status: ENROLLING_BY_INVITATION